APLM APOLLOMICS INC.

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY.

H.C. Wainwright 26th Annual Global Investment Conference

Format: Company presentation

Presentation Date & Time: Available on demand as of September 9, 2024 at 7:00 am ET

Presenters: Guo-Liang Yu, PhD, Chairman and Chief Executive Officer and Matthew Plunkett, PhD, Chief Financial Officer

Webcast: Click

Management will be available for virtual one-on-one meetings during the conference. Interested investors should contact their H.C. Wainwright representative to request meetings. The Company’s current presentation may be accessed on the Company website on the page under the Investors section.

About  

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ programs include its lead product candidate, vebreltinib, a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort global clinical trial, and uproleselan, a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in a Phase 3 clinical trial in China. For more information, please visit .

Investor Contact:

Eric Ribner

LifeSci Advisors, LLC

(646) 751-4363

 



EN
04/09/2024

Underlying

APLMAPOLLOMICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on APOLLOMICS INC.

 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Reports Full Year 2024 Financial Results and Highlights Cli...

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification$9.8 million in cash and cash equivalents as of December 31, 2024, in conjunction with LaunXP upfront payment, pipeline focus and exp...

April 3, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics and LaunXP Announce Development and Commercialization Agree...

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer (“NSCLC”)Apollomics to receive upfront payments of $10 million, and is eligible for pre-commercial milestones up to $50 million, and royalties on net product sales FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apo...

March 31, 2025 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Up...

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not de...

December 20, 2024 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirem...

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on December 10, 2024, it received a notification (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Rule 5550(a)(2) (the “Bid Price R...

December 10, 2024 1 EN
 PRESS RELEASE
Free
APLM APOLLOMICS INC.

Apollomics’ Announces Shareholder Approval and Effective Date for 1-fo...

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024 FOSTER CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it will affect a 1-for-100 reverse share split (“Reverse Share Split”) of its class A ordinary sh...

November 21, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch